1848 related articles for article (PubMed ID: 8369752)
1. Pharmacokinetic characteristics and antitumor activity of the N-succinyl-chitosan-mitomycin C conjugate and the carboxymethyl-chitin-mitomycin C conjugate.
Song Y; Onishi H; Nagai T
Biol Pharm Bull; 1993 Jan; 16(1):48-54. PubMed ID: 8369752
[TBL] [Abstract][Full Text] [Related]
2. In vivo drug release and antitumor characteristics of water-soluble conjugates of mitomycin C with glycol-chitosan and N-succinyl-chitosan.
Sato M; Onishi H; Takahara J; Machida Y; Nagai T
Biol Pharm Bull; 1996 Sep; 19(9):1170-7. PubMed ID: 8889036
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and drug-release characteristics of the conjugates of mitomycin C with N-succinyl-chitosan and carboxymethyl-chitin.
Song Y; Onishi H; Nagai T
Chem Pharm Bull (Tokyo); 1992 Oct; 40(10):2822-5. PubMed ID: 1464115
[TBL] [Abstract][Full Text] [Related]
4. Biological fate of highly-succinylated N-succinyl-chitosan and antitumor characteristics of its water-soluble conjugate with mitomycin C at i.v. and i.p. administration into tumor-bearing mice.
Kato Y; Onishi H; Machida Y
Biol Pharm Bull; 2000 Dec; 23(12):1497-503. PubMed ID: 11145185
[TBL] [Abstract][Full Text] [Related]
5. In vivo properties of the conjugates of mitomycin C with estradiol benzoate and estradiol: pharmacokinetics and antitumor characteristics against P388 leukemia and sarcoma 180.
Ishiki N; Onishi H; Machida Y
Biol Pharm Bull; 1998 Nov; 21(11):1180-6. PubMed ID: 9853409
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of lactosaminated and intact N-succinylchitosan-mitomycin C conjugates against M5076 liver metastatic cancer.
Kato Y; Onishi H; Machida Y
J Pharm Pharmacol; 2002 Apr; 54(4):529-37. PubMed ID: 11999131
[TBL] [Abstract][Full Text] [Related]
7. Lactosaminated and intact N-succinyl-chitosans as drug carriers in liver metastasis.
Kato Y; Onishi H; Machida Y
Int J Pharm; 2001 Sep; 226(1-2):93-106. PubMed ID: 11532574
[TBL] [Abstract][Full Text] [Related]
8. N-succinyl-chitosan as a drug carrier: water-insoluble and water-soluble conjugates.
Kato Y; Onishi H; Machida Y
Biomaterials; 2004 Feb; 25(5):907-15. PubMed ID: 14609679
[TBL] [Abstract][Full Text] [Related]
9. Preparation and drug release characteristics of the conjugates of mitomycin C with glycol-chitosan and N-succinyl-chitosan.
Sato M; Onishi H; Kitano M; Machida Y; Nagai T
Biol Pharm Bull; 1996 Feb; 19(2):241-5. PubMed ID: 8850315
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of mitomycin C-dextran conjugate against various murine tumors.
Hashida M; Kato A; Kojima T; Muranishi S; Sezaki H; Tanigawa N; Satomura K; Hikasa Y
Gan; 1981 Apr; 72(2):226-34. PubMed ID: 6169584
[TBL] [Abstract][Full Text] [Related]
11. Preparation and in vitro properties of N-succinylchitosan- or carboxymethylchitin-mitomycin C conjugate microparticles with specified size.
Onishi H; Takahashi H; Yoshiyasu M; Machida Y
Drug Dev Ind Pharm; 2001 Aug; 27(7):659-67. PubMed ID: 11694013
[TBL] [Abstract][Full Text] [Related]
12. Contribution of chitosan and its derivatives to cancer chemotherapy.
Kato Y; Onishi H; Machida Y
In Vivo; 2005; 19(1):301-10. PubMed ID: 15796190
[TBL] [Abstract][Full Text] [Related]
13. Characteristics of the antitumor activity of M-16 and M-18, major metabolites of a new mitomycin C derivative KW-2149, in mice.
Ashizawa T; Okamoto A; Okabe M; Kobayashi S; Arai H; Saito H; Kasai M; Gomi K
Anticancer Drugs; 1995 Dec; 6(6):763-70. PubMed ID: 8845489
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity and toxicity in animals of N-7[2-(4-nitrophenyldithio) ethyl] mitomycin C (BMY-25067).
Bradner WT; Rose WC; Schurig JE; Florczyk AP
Invest New Drugs; 1990; 8 Suppl 1():S1-7. PubMed ID: 2380013
[TBL] [Abstract][Full Text] [Related]
15. Tumour cell uptake of lactosaminated and intact N-succinyl-chitosans and antitumour effects of conjugates with mitomycin C.
Kato Y; Onishi H; Machida Y
Anticancer Res; 2002; 22(5):2771-6. PubMed ID: 12529995
[TBL] [Abstract][Full Text] [Related]
16. Preparation and antitumor activities of mitomycin C beta-(1-->6)-branched (1-->3)-beta-D-glucan conjugate.
Usui S; Murashima K; Sakai M; Kiho T; Ukai S
Biol Pharm Bull; 1994 Sep; 17(9):1165-70. PubMed ID: 7841935
[TBL] [Abstract][Full Text] [Related]
17. Mitomycin C combination therapy against murine tumor systems. Effectiveness with cyclophosphamide and methotrexate.
Mabel JA; Wodinsky I
Cancer; 1983 Feb; 51(4):600-5. PubMed ID: 6401590
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo anti-tumor activity of L-glutamic acid gamma-monohydroxamate against L1210 leukemia and B16 melanoma.
Vila J; Thomasset N; Navarro C; Doré JF
Int J Cancer; 1990 Apr; 45(4):737-43. PubMed ID: 2323850
[TBL] [Abstract][Full Text] [Related]
19. Flavone acetic acid increases the cytotoxicity of mitomycin C when combined with hyperthermia.
Takeuchi H; Baba H; Maehara Y; Sugimachi K; Newman RA
Cancer Chemother Pharmacol; 1996; 38(1):1-8. PubMed ID: 8603441
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity and toxicity in animals of BMY-25282, a new mitomycin derivative.
Bradner WT; Rose WC; Schurig JE; Florczyk AP; Huftalen JB; Catino JJ
Cancer Res; 1985 Dec; 45(12 Pt 1):6475-81. PubMed ID: 3933826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
